文献速递类风湿关节炎

类风湿关节炎患者启动改善病情抗风湿药前使用计算机断层扫描筛查恶性肿瘤

Computed tomography for malignancy screening in patients with rheumatoid arthritis before initiation of disease modifying antirheumatic drug.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

本研究纳入2192例活动性RA患者,在启动生物制剂和靶向合成DMARDs前进行平扫CT筛查,33例(1.5%)检出恶性肿瘤,其中26例为常规筛查未发现(19例早期);CT筛查后启动b/tsDMARDs的患者5年恶性肿瘤发生率低于无CT筛查队列(标准化发病比0.35)。结论认为CT筛查有助于早期发现和治疗恶性肿瘤,使b/tsDMARD治疗更安全稳定。

要点

  • 2192例RA患者中CT筛查检出恶性肿瘤33例(1.5%),常规筛查仅检出7例
  • CT筛查额外检出26例恶性肿瘤,其中19例为早期
  • CT筛查后启动b/tsDMARDs的患者5年恶性肿瘤发生率低于无CT筛查队列(标准化发病比0.35)

核心结论

  • 在启动b/tsDMARDs前对RA患者进行CT筛查可实现恶性肿瘤的早期发现和治疗,从而使b/tsDMARD治疗更安全、更稳定。

研究设计与样本

  • 研究纳入2192例在启动b/tsDMARDs前接受平扫CT扫描的RA患者,比较CT筛查与常规筛查(体格检查和X线)的恶性肿瘤检出敏感性,并评估合并恶性肿瘤患者的临床特征、预后和治疗,以及CT筛查后启动b/tsDMARDs患者的恶性肿瘤发生率。

主要发现

  • 2192例患者中33例(1.5%)经CT筛查诊断为恶性肿瘤。
  • 常规筛查仅检出7例恶性肿瘤,CT筛查额外检出26例,其中19例为早期。
  • 常规筛查可检出的恶性肿瘤中86%为晚期。
  • 诊断为早期恶性肿瘤的患者在根治性切除后接受包括b/tsDMARDs在内的RA治疗,其中80%在1年后达到低疾病活动度,与筛查未检出恶性肿瘤的患者(70%)相当。
  • CT筛查后启动b/tsDMARDs的患者5年恶性肿瘤发生率低于无CT筛查的RA队列(标准化发病比:0.35)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to clarify the usefulness of screening for malignancies using CT before the initiation of biologic and targeted synthetic DMARDs (b/tsDMARDs) in patients with active RA. METHODS: We examined 2192 patients with RA who underwent plain CT scans prior to the initiation of b/tsDMARDs. The sensitivity for detecting malignancy was measured and compared with that of regular screening (physical examination and X-ray). We then evaluated the clinical characteristics, prognosis and treatment of patients with RA with concomitant malignancies. Additionally, we determined the incidence rate of malignancy in patients with RA who were initiated on b/tsDMARDs after CT screening. RESULTS: Of the 2192 patients, 33 (1.5%) were diagnosed with malignancy after CT screening. Whereas regular screening detected only seven malignancies, CT screening further detected 26 (including 19 at the early stage). On the other hand, 86% of the malignancies detectable by regular screening were at an advanced stage. Patients diagnosed with early-stage malignancies received RA treatments that included b/tsDMARDs after curative resection; 80% of these patients achieved low disease activity after 1 year. This rate was comparable to the patients without malignancy detection after screening (70%). The 5 year incidence of malignancy after the initiation of b/tsDMARDs after CT screening was lower than that of the RA cohort without CT screening (standardized incidence ratio: 0.35). CONCLUSION: Screening in patients with RA using CT before the initiation of b/tsDMARDs allows for the early detection and treatment of malignancy, resulting in safer and more stable b/tsDMARD treatments.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Miyata H, Sonomoto K, Fukuyo S, et al. Computed tomography for malignancy screening in patients with rheumatoid arthritis before initiation of disease modifying antirheumatic drug. Rheumatology (Oxford). 2023. PMID: 36782362. doi:10.1093/rheumatology/kead075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。